Advertisement

Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Genmab (Group)

Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer. Founded in 1999, the company has two approved antibodies, DARZALEX® (daratumumab) for the treatment of certain multiple myeloma indications, and Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications. Daratumumab is in clinical development for additional multiple myeloma indications, other blood cancers and amyloidosis. A subcutaneous formulation of ofatumumab is in development for relapsing multiple sclerosis. Genmab also has a broad clinical and pre-clinical product pipeline. Genmab's technology base includes a number of proprietary next generation antibody technologies Genmab has alliances with other leading pharmaceutical and biotechnology companies. *

 

Period Start 1999-01-01 established
  Today Genmab A/S (Nasdaq Copenhagen: GEN)
Products Industry DuoBody technology platform (bispecific antibodies)
  Industry 2 Darzalex®
Person Person van de Winkel, Jan (Genmab 201106 CEO before CSO + Co-Founder before Medarex Europe)
     
Region Region København (Copenhagen)
  Country Denmark
  Street 43 Kalvebod Brygge
  City 1560 Copenhagen V
  Tel +45-70-202728
    Address record changed: 2019-07-14
     
Basic data Employees D: 101 to 500 (2016-12-31)
  Currency DKK
  Annual sales 1,816,122,000 (revenue, consolidated (2016) 2016-12-31)
  Profit 1,187,075,000 (2016-12-31)
  Cash 307,023,000 (2016-12-31)
     
    * Document for �About Section�: Genmab A/S. (7/12/19). "Press Release: Genmab and Blink Biomedical Enter into Commercial License Agreement". Copenhagen.
     
   
Record changed: 2019-07-14

Advertisement

Picture [LSUS] Life-Sciences-USA.com – The Business Web Portal 650x112px

More documents for Genmab (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group BioPharm America 2019 Boston September 650x65px




» top